Tocainidum [INN-Latin] en es it fr

Tocainidum [INN-Latin] Brand names, Tocainidum [INN-Latin] Analogs

Tocainidum [INN-Latin] Brand Names Mixture

  • No information avaliable

Tocainidum [INN-Latin] Chemical_Formula


Tocainidum [INN-Latin] RX_link

Tocainidum [INN-Latin] fda sheet

Tocainidum_[INN-Latin] FDA

Tocainidum [INN-Latin] msds (material safety sheet)

Tocainidum_[INN-Latin] MSDS

Tocainidum [INN-Latin] Synthesis Reference

No information avaliable

Tocainidum [INN-Latin] Molecular Weight

500.548 g/mol

Tocainidum [INN-Latin] Melting Point

No information avaliable

Tocainidum [INN-Latin] H2O Solubility

>16 mg/ml at 25.0°C

Tocainidum [INN-Latin] State


Tocainidum [INN-Latin] LogP


Tocainidum [INN-Latin] Dosage Forms

Sterile ophthalmic solution (0.004%) with a pH of approximately 6.0 and an osmolality of approximately 290 mosmol/kg.

Tocainidum [INN-Latin] Indication

Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

Tocainidum [INN-Latin] Pharmacology

Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F analogue. Travoprost reduces pressure in the eye by increasing the amount of fluid that drains from the eye.

Tocainidum [INN-Latin] Absorption

Systemically absorbed when administered to the eye.

Tocainidum [INN-Latin] side effects and Toxicity

Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.

Tocainidum [INN-Latin] Patient Information

No information avaliable

Tocainidum [INN-Latin] Organisms Affected

Humans and other mammals